Envisia Therapeutics, a startup that was spun off from Liquidia, has hired a veteran exexutive from Pappas Ventures – one of its investors – to serve as CFO.

Taking the chief financial officer position is Eric Linsley, one of the managing partners at Durham-based Pappas.

Liquidia spun off Envisia in 2013 with $25 million in funding. Neal Fowler is CEO of both companies.

Pappas, which focuses on life science investments, is listed as an Envisia investor.

The focus of the startup is ophthalmology. The company is seeking to capitalize on Liquidia’s existing nano technology platform known as PRINT in pursuing eye treatments.

Linsley has worked at Pappas since 2000. His appointment was announced Thursday.

Linsley “was directly responsible for investments that led to several very successful acquisitions and public offerings. He brings with him more than 20 years of experience and a proven track record of finance and life science investment expertise,” Envisia noted.

Added Envisia president and co-founder Benjamin Yerxa:

“Eric’s rich background of operational, financial and investor knowledge will play an important role in helping us to continue building Envisia’s value proposition while we advance our clinical programs toward several important milestones.”

The management hire is the second for Envisia in recent months. In April, Envisia named Dr. Rhett Schiffman as its chief medical officer.

Linsley has more than 20 years of experience in life science management.

Linsley’s record

Here is Lisnle\’s management resume as cited by Envisia:

“While at Pappas Ventures, Mr. Linsley served on the Board of Panacos Pharmaceuticals Inc. (Nasdaq: PANC) and played a key role in its successful reverse merger with a publicly traded company. He was also directly responsible for investments in Peninsula Pharmaceuticals, Inc., which Johnson & Johnson acquired in 2005 at a substantial premium, and later Cerexa, Inc., which was acquired by Forest Laboratories, Inc. in 2007. Other representative investments include Balance Therapeutics, Inc., FlowCardia, Inc. (acquired by Bard Pharmaceuticals), LipoScience, Inc. (acquired by LabCorp), Liquidia Technologies, Milestone Pharmaceuticals Inc., Ultragenyx Pharmaceutical Inc. (Nasdaq: RARE), and Envisia Therapeutics.

“Prior to joining Pappas Ventures in 2000, Mr. Linsley served as Chief Financial Officer of TriPath Imaging, Inc. (Nasdaq: TPTH), a medical device company acquired by Becton, Dickinson and Company in 2006. He also played a key role in facilitating the three-way merger between AutoCyte, Inc., NeoPath (Nasdaq: NPTH) and Neuromedical Systems Inc. (Nasdaq: NSIX) to form TriPath Imaging, Inc. in 1999. Prior to the formation of TriPath, he led AutoCyte, the predecessor company, in a successful public stock offering in 1997.

“Mr. Linsley also worked as an investment professional with Ampersand Capital, a leading life sciences investor based in Boston. While at Ampersand, he held several management positions in operating and financial roles for various industrial products and life sciences companies. Early in his career, he served as a management consultant with Bain & Co. and McKinsey & Co., and was a Certified Public Accountant with Arthur Andersen LLP.”